Propanc Biopharma, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $4.7M
- Price
- $0.4749
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.76%
- Volume
- 181.1K
About
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
Quick stats
Shares outstanding9.8M
Computed float5.4M
Float / shares54.6%
Cash runway (months)1
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001517681
Websitehttps://www.propanc.com
AI Summary
AI-generated1/27
standardbullishclinical trial
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
Propanc Biopharma highlighted new preclinical data for its lead candidate PRP in pancreatic ductal adenocarcinoma, showing greater than 90% mean tumor growth inhibition versus vehicle (p < 0.001) and a median overall survival extension of more than 2.5-fold versus controls in animal models.
PRP also reduced liver and peritoneal metastases, remodeled the tumor microenvironment, and re-sensitized chemo-resistant PDAC cells to gemcitabine plus nab-paclitaxel. Unlike newly FDA-approved daraxonrasib (Revolution Medicines), PRP targets EMT, cancer stem cells, and fibrosis rather than RAS signaling, and is not RAS-genotype restricted.
The company plans a multicenter Phase 1b first-in-human study of PRP in Q1 2027, enrolling up to 50 patients with advanced solid tumors at Australian sites. CEO James Nathanielsz positioned PRP as a potential combination or sequential partner to RAS inhibitors rather than a substitute.
Red flags
- all efficacy data are preclinical (animal models); no clinical trial results yet for PRP
- clinical experience limited to compassionate-use cases, not controlled studies
- first-in-human trial not expected until Q1 2027